Phase II study of cisplatin, pemetrexed plus bevacizumab for EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell lung cancer)

Phase II study of cisplatin, pemetrexed plus bevacizumab for EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell lung cancer) - Phase II study of CDDP/PEM/BEV for EGFR mutation negative stage III/IV non-small-cell lung cancer)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003855

Enrollment

Registered

2010-07-01

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell carcinoma)

Interventions

cisplatin 75mg/m2 (day1), pemetrexed 500mg/m2 (day1) and bevacizumab 15mg/kg (day1), every 3-4 weeks, total 3-6 courses. After that, bevacizumab 15mg/kg (day1), every 3-4 weeks until PD.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Non-small-cell (Non-squamous cell) lung cancer 2)Unresectable stage III/IV and postoperative relapsed cases 3)EGFR mutation negative or unknown 4)Chemotherapy naive 5)Target lesion is measurable 6)More than 20 years old, less than 75 years old 7)Expected survival is more than 12 weeks 8)ECOG Perfomance Status 0-1 9)Adequate hematologic, hepatic, and renal functions 10)More than 2 weeks rest period after palliative radiation or control of pleural effusion 11)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Massive pleural effusion 2)Massive pericardial effusion 3)Double cancer 4)Severe complications; myocardial infarction, unstable angina, heart failure, uncontrolled hypertension, and unconrolled diabetis mellitus, uncontrolled infection, uncontrolled mental disease, SVC syndrome 5)Hemoptysis(more than 2.5ml), continuous or treatment-required bloody sputum 6)Invasion to large vessels, cavity in tumor 7)Brain metastsis 8)Under anti-coagulation therapy 9)Bleeding 10)Nephrosis 11)Uncured wound 12)Digestive tract ulcer, diverticulosis 13)Bone marrow suppression 14)Lung fibrosis 15)Pregnancy 16)Other inappropriate cases

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
overall survival, progression disease free survival, adverse event rate	—

Countries

Japan

Contacts

Public ContactHaruhiro Saito

Kanagawa Cancer Center Thoracic Oncology

saito-h@kcch.jp045-391-5761

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026